Image
Cell Metabolism Tuesday, December 4, 2018

The microenvironment influences cancer drug response and sustains resistance to therapies targeting receptor-tyrosine kinases. However, if and how the tumor microenvironment can be altered during...

Lancet Oncology Tuesday, September 11, 2018

BACKGROUND:
Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our...

Jci Friday, August 31, 2018

Cancer cell dependence on activated oncogenes is therapeutically targeted, but acquired resistance is virtually unavoidable. Here we show that the treatment of addicted melanoma cells with BRAF...

Cancer Research Sunday, July 1, 2018

USP6NL, also named RN-tre, is a GTPase-activating protein involved in control of endocytosis and signal transduction. Here we report that USP6NL is overexpressed in breast cancer, mainly of the...

Nature Communications Tuesday, June 12, 2018

Mariangela Russo, Simona Lamba, Annalisa Lorenzato, Alberto Sogari, Giorgio Corti, Giuseppe Rospo, Benedetta Mussolin, Monica Montone, Luca Lazzari, Sabrina Arena, Daniele Oddo, Michael...

Science Translational Medicine Tuesday, May 29, 2018

Semaphoring to tumor vasculature

Solid tumors typically have blood vessels that are not only increased in number but also exhibit various structural and functional...

Nature Thursday, December 7, 2017

Molecular alterations in genes involved in DNA mismatch repair (MMR) promote cancer initiation and foster tumour progression. Cancers deficient in MMR frequently show favourable prognosis and...

Lancet Oncology Tuesday, August 30, 2016

Background: Cancer of unknown primary ranks in the top ten cancer presentations and has an extremely poor prognosis. Identification of the primary tumour and development of a tailored site-...

Cancer Discovery Monday, June 20, 2016

A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy...

Sci Transl Med Monday, February 29, 2016

Abstract
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab are used to treat RAS wild-type colorectal cancers (CRCs), but their efficacy is limited by the...

 

Reach us